Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapies, has announced new employment inducement grants. The company's Compensation Committee has approved equity awards for twelve new employees, consisting of:
- Options to purchase 42,920 shares of common stock at $9.12 per share (closing price on March 24, 2025)
- Restricted stock units (RSUs) for 21,650 shares of common stock
These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS), un'azienda biofarmaceutica in fase clinica specializzata in terapie oncologiche, ha annunciato nuovi incentivi per l'assunzione. Il Comitato per la Compensazione dell'azienda ha approvato premi azionari per dodici nuovi dipendenti, che consistono in:
- Opzioni per l'acquisto di 42.920 azioni ordinarie a $9,12 per azione (prezzo di chiusura del 24 marzo 2025)
- Unità di azioni vincolate (RSU) per 21.650 azioni ordinarie
Questi premi azionari sono stati concessi nell'ambito del Piano di Induzione 2020 dell'azienda, istituito nel gennaio 2020 secondo l'eccezione del Regolamento 303A.08 del Manuale delle Aziende Quotabili NYSE.
Arcus Biosciences (NYSE:RCUS), una empresa biofarmacéutica en etapa clínica especializada en terapias contra el cáncer, ha anunciado nuevas concesiones de incentivos laborales. El Comité de Compensación de la empresa ha aprobado premios de acciones para doce nuevos empleados, que consisten en:
- Opciones para comprar 42,920 acciones ordinarias a $9.12 por acción (precio de cierre del 24 de marzo de 2025)
- Unidades de acciones restringidas (RSUs) para 21,650 acciones ordinarias
Estos premios de acciones se otorgaron bajo el Plan de Inducción 2020 de la empresa, que se estableció en enero de 2020 bajo la excepción de inducción de la Regla 303A.08 del Manual de Empresas Cotizadas de la NYSE.
Arcus Biosciences (NYSE:RCUS), 암 치료를 전문으로 하는 임상 단계의 바이오 제약 회사가 새로운 고용 유인 보상을 발표했습니다. 회사의 보상 위원회는 12명의 신규 직원에게 주식 보상을 승인했으며, 이는 다음과 같습니다:
- 주당 $9.12(2025년 3월 24일 종가)로 42,920주를 구매할 수 있는 옵션
- 21,650주에 대한 제한 주식 단위(RSU)
이 주식 보상은 2020년 1월에 설립된 회사의 2020 유인 계획에 따라 부여되었습니다. 이 계획은 NYSE 상장 회사 매뉴얼 규칙 303A.08의 유인 예외에 따라 설정되었습니다.
Arcus Biosciences (NYSE:RCUS), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies contre le cancer, a annoncé de nouvelles subventions d'incitation à l'emploi. Le Comité de Rémunération de l'entreprise a approuvé des attributions d'actions pour douze nouveaux employés, qui se composent de :
- Options d'achat de 42 920 actions ordinaires à 9,12 $ par action (prix de clôture du 24 mars 2025)
- Unités d'actions restreintes (RSU) pour 21 650 actions ordinaires
Ces attributions d'actions ont été accordées dans le cadre du Plan d'Incitation 2020 de l'entreprise, qui a été établi en janvier 2020 selon l'exception d'incitation de la Règle 303A.08 du Manuel des Sociétés Cotées de la NYSE.
Arcus Biosciences (NYSE:RCUS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Krebstherapien spezialisiert hat, hat neue Anreizvergaben für die Beschäftigung angekündigt. Der Vergütungsausschuss des Unternehmens hat Aktienvergaben für zwölf neue Mitarbeiter genehmigt, die aus Folgendem bestehen:
- Optionen zum Kauf von 42.920 Stammaktien zu einem Preis von 9,12 $ pro Aktie (Schlusskurs am 24. März 2025)
- Restricted Stock Units (RSUs) für 21.650 Stammaktien
Diese Aktienvergaben wurden im Rahmen des Unternehmensplans zur Anreizung von 2020 gewährt, der im Januar 2020 gemäß der Ausnahme für Anreize gemäß Regel 303A.08 des NYSE-Listenunternehmenshandbuchs eingerichtet wurde.
- None.
- None.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325275972/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Maryam Bassiri
AD, Corporate Communications
(510) 406-8520
mbassiri@arcusbio.com
Source: Arcus Biosciences
FAQ
What equity awards did Arcus Biosciences (RCUS) grant to new employees in March 2025?
What is the exercise price for RCUS stock options granted in March 2025?
How many new employees received RCUS equity awards in March 2025?
Under which plan were the RCUS equity awards granted in March 2025?
